Universal Screening for Vocal Fold Motion Impairment in Children Undergoing Congenital Cardiac Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children 18 and younger with congenital cardiac disease necessitating surgery
- Children 18 and younger whose parents have given and signed an informed consent and HIPAA Authorization as well as the assent of the patient
Exclusion Criteria:
- History of prior cardiac surgery
- Known history of VFMI prior to evaluation
- Children 18 and younger who do not survive the immediate postoperative course will be excluded.
- Further exclusion may be determined at the discretion of the Principal Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Neonates with congenital cardiac disease (retrospective)
Medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016 will be reviewed.
Those who developed VFMI following CCS as diagnosed on flexible fiberoptic laryngoscopy will be identified.
Inpatient, outpatient and emergency department (ED) records will be studied for details on postoperative length of stay, time to diagnosis of VFMI, time to initiation of oral feeding, ED visits and readmissions for feeding/weight gain or respiratory issues, and otolaryngology intervention.
|
|
|
Active Comparator: Neonates with congenital cardiac disease (prospective)
Eligible children with known congenital cardiac disease necessitating cardiothoracic surgery will undergo universal screening, i.e., laryngeal ultrasonography and flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if they are not intubated and are stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope and portable ultrasound system while awake.
|
Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.
Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative length of stay (retrospective)
Time Frame: Baseline
|
The number of days of postoperative stay in the hospital will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.
|
Baseline
|
|
Number of readmissions related to feeding difficulty (retrospective)
Time Frame: Baseline
|
The number of readmissions to the hospital for feeding difficulties will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.
|
Baseline
|
|
Number of readmissions related to aspiration (retrospective)
Time Frame: Baseline
|
The number of readmissions to the hospital for aspiration will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.
|
Baseline
|
|
Time to initiation of feeding therapy (retrospective)
Time Frame: Baseline
|
The average time (in days) to start feeding therapy will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.
|
Baseline
|
|
Number of participants with vocal fold motion impairment (prospective)
Time Frame: Baseline
|
The number of study participants diagnosed with VFMI following CCS universal screening will be recorded.
|
Baseline
|
|
Postoperative length of stay (prospective)
Time Frame: Up to 180 days
|
The number of days of postoperative stay at the hospital will be recorded.
|
Up to 180 days
|
|
Time to initiation of feeding therapy (prospective)
Time Frame: Day 7
|
The number of days to start feeding therapy will be recorded.
|
Day 7
|
|
Number of readmissions related to aspiration (prospective)
Time Frame: 3 months, 6 months, 12 months
|
The number of readmissions to the hospital for aspiration will be recorded.
|
3 months, 6 months, 12 months
|
|
Number of readmissions related to feeding difficulty (prospective)
Time Frame: 3 months, 6 months, 12 months
|
The number of readmissions to the hospital for feeding difficulties will be recorded.
|
3 months, 6 months, 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nikhila Raol, MD, MPH, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neurologic Manifestations
- Congenital Abnormalities
- Otorhinolaryngologic Diseases
- Cranial Nerve Diseases
- Cardiovascular Abnormalities
- Paralysis
- Laryngeal Diseases
- Vagus Nerve Diseases
- Heart Diseases
- Heart Defects, Congenital
- Vocal Cord Paralysis
Other Study ID Numbers
Other Study ID Numbers
- IRB00093935
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.